Commentary - (2022) Volume 9, Issue 5

Botulinum Toxin-A Therapy for Neurogenic and Non-Neurogenic Bladders in Pediatric Urology

Gupta DK1*
*Correspondence: Gupta DK, Department of Pediatric Surgery, TNMC and BYL Nair Hospital, Mumbai, India, Email:

Author info »


After being discovered in the late 1700s, van Ermegam began using botulinum toxin-A for medical treatment in 1897. It is a facultative anaerobe that prevents the release of acetylcholine at the neuromuscular junction by irreversibly interacting with receptors at the presynaptic cholinergic junction. It affects the protein SNAP 25. Acetylcholine levels are low, which prevents muscles from contracting and effectively paralyses them. The effect typically lasts between one and three months before new terminal axons start to sprout. In order to lessen its potentially morbid side effects, end-organ therapies have been the main focus of Botulinum Toxin-A use in human illness. Like most specialists, urologists have recently increased their use of Botulinum Toxin-A and enlarged their interests in the toxin, primarily in the subspecialty of neurourology. In addition to treating Overactive Bladder (OAB) and sphincter dyssynergy, doctors are increasingly employing it to treat bladder pain brought on by interstitial cystitis as well as to diminish chronic elevated tonicity of the pelvic floor (and its accompanying musculature). Its impact on c-fibers, substance P, and glutamate appears to have an analgesic effect on chronic inflammation. The current off-label indications in urology include OAB, interstitial cystitis, incontinence, neurogenic detrusor dysfunction, non-neuogenic and neurogenic sphincter dyssynergy, and prostatitis. The usage of Botulinum Toxin-A in neurogenic and non- neurogenic bladders is the main topic of discussion in the paediatric literature. The drug is used to treat excessive bladder pressures and incontinence brought on by both spontaneous and dysfunctional sphincters. Pediatric urologists are starting to accept Botulinum Toxin-A as a treatment for kids with refractory voiding dysfunction/ daytime incontinence and non-neurogenic internal and external sphincter dyssynergy as its safety and efficacy are continuing to be demonstrated. Injections of both the detrusor and the urethral sphincter have been recorded in the juvenile urologic literature with doses ranging from 50 to 300 units of Botulinum Toxin-A-A per dosage. Kind, quantity, dilution volume (there is no agreement in the literature), injection site, number of injections, depth of injections, equipment, and type of anaesthetic are all factors in urologic toxin delivery. The dose must be given intravascularly in order to be fatal. Never administer therapeutic Botulinum Toxin-A intravenously. Among the adverse effects mentioned in the urologic literature are localised muscle weakness and urine retention, both of which universally go away after the linked nerves’ axonal regeneration (usually within 1–3 months). These effects have been observed in individuals being treated for OAB in particular, and they are assumed to be caused by the Botulinum Toxin-A migrating out from the detrusor muscle. Children were exposed to doses of between 6.25 and 32 units/kg of botulinum toxin-A (Botox and Dysport) and between 388 and 625 units/kg of botulinum toxin type B, which have been associated with significant side effects (Myobloc). When children were given Botulinum Toxin-A for urologic indications, none of these issues materialised. Adults have received injections in office-like settings in certain studies. It can take anywhere from 7 to 30 days for the normal onset of action. The normal onset of effect is between 5 and 7 days in our own patients. Under general anaesthesia, the poison is administered into children. When Botulinum Toxin-A was injected into the external sphincter, they found that the typical duration of activity was 12 to 18 weeks. Effects from an injection into the detrusor can linger for up to six months. 15 kids were given injections for neurogenic bladder at a rate of 10 units/kg, up to a maximum of 360 units, by Riccabona and companions. They all had a considerable reduction in bladder pressure over the course of a mean of 10.5 months. In a study by Kajbafzadeh, she described the intravesical injection of Botulinum Toxin-A for neurogenic bowel and bladder in children with myelomeningocele. Four months after the procedure, 73% of all the children were dry between clean intermittent catheterizations, 88% showed overall improvement in symptoms, and 73% had a decline in the grade of their reflux. The improvement of supersensitivity in OAB and defective voiding is thought to be due to the Botulinum Toxin- effects A’s on the sensory aspect of the reflex arc rather than only the detrusor’s motor action in children with OAB. According to a prospective study by Hoebeke et al., 21 patients (10 men and 11 women) had cystoscopic detrusor injections with 100 units of botulinum toxin-A for hyperactive detrusors that were refractory to therapy. Nine kids had a full reaction to one injection out of the 15 patients who were monitored for more than six months, and three kids had a partial response. One youngster got a full response to a second injection out of the three partial responders.


Children with refractory neurogenic and non-neurogenic voiding dysfunction may benefit from a safe and effective treatment option called botulinum toxin-A injections into the detrusor and external sphincter. The use of other therapies, such as combination sphincteric and trigonal injection, that have previously been used in the adult population, is currently being investigated in the paediatric population. All treatments require long-term monitoring, and some patients may need further injections.

Author Info

Gupta DK1*
Department of Pediatric Surgery, TNMC and BYL Nair Hospital, Mumbai, India

Received: 27-Sep-2022, Manuscript No. PUCR-22- 80899; , Pre QC No. PUCR-22- 80899; Editor assigned: 29-Sep-2022, Pre QC No. PUCR-22- 80899; Reviewed: 12-Oct-2022, QC No. PUCR-22- 80899; Revised: 21-Oct-2022, Manuscript No. PUCR-22- 80899; Published: 28-Oct-2022, DOI: 10.14534/j-pucr.20222675589

Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Get the App